Spain's competition watchdog opened an investigation into whether drug makers including Sandoz and its subsidiary Bexal broke antitrust rules by sharing sensitive commercial information.
Spain's competition watchdog opened an investigation into whether drug makers including Sandoz and its subsidiary Bexal broke antitrust rules by sharing sensitive commercial information.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback